SCHEMBL5114077

SCHEMBL5114077

C1CCC([C@@H]2CCNC2)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
CCR5 P51681 1/20 0.37
HTR2C P28335 1/20 0.35
HTR6 P50406 1/20 0.34
HTR3A P46098 1/20 0.32
SLC6A1 P30531 3/20 0.31
SLC6A11 P48066 2/20 0.31
SLC6A13 Q9NSD5 2/20 0.31
KCNH2 Q12809 1/20 0.31
TSHR P16473 1/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PNMT P11086 1/20 0.30
APLNR P35414 2/20 0.30
KDM4E B2RXH2 1/20 0.30
MAPT P10636 1/20 0.30
KMT2A Q03164 1/20 0.30
ATM Q13315 1/20 0.30
NOS2 P35228 1/20 0.30
CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8017282 1.00 ALDH1A1 (0.47) ALDH1A1CCR5HTR2CHTR6HTR3A
SCHEMBL1037842 1.00 ALDH1A1 (0.47) ALDH1A1CCR5HTR2CHTR6HTR3A
SCHEMBL14620877 1.00 ALDH1A1 (0.47) ALDH1A1CCR5HTR2CHTR6HTR3A
SCHEMBL6426932 1.00 ALDH1A1 (0.47) ALDH1A1CCR5HTR2CHTR6HTR3A
SCHEMBL165540 1.00 ALDH1A1 (0.47) ALDH1A1CCR5HTR2CHTR6HTR3A
SCHEMBL24912524 1.00 ALDH1A1 (0.47) ALDH1A1CCR5HTR2CHTR6HTR3A
SCHEMBL14772 1.00 ALDH1A1 (0.47) ALDH1A1CCR5HTR2CHTR6HTR3A
SCHEMBL1037843 1.00 ALDH1A1 (0.47) ALDH1A1CCR5HTR2CHTR6HTR3A
SCHEMBL22540086 1.00 ALDH1A1 (0.47) ALDH1A1CCR5HTR2CHTR6HTR3A
SCHEMBL12440357 1.00 ALDH1A1 (0.47) ALDH1A1CCR5HTR2CHTR6HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2023-11-02 US disclosed
CN-101622242-B Bicyclic derivatives as CETP inhibitors NOVARTIS AG 2013-07-17 CN disclosed
CN-101622242-A Bicyclic derivatives as CETP inhibitors NOVARTIS AG 2010-01-06 CN disclosed
CN-101389606-A Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (CETP) NOVARTIS AG (CH) 2009-03-18 CN disclosed
US-7465751-B2 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-16 US disclosed
US-20060194862-A1 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists RANBAXY LABORATORIES LIMITED (IN) 2006-08-31 US disclosed
EP-1583741-A1 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories, Limited (IN) 2005-10-12 EP disclosed
WO-2004056767-A1 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194862-A1 1-Substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists CHRM3, CHRM1, CHRM5 ALDH1A1 821/4885CCR5 191/4885HTR2C 264/4885
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION POLRMT, DCLRE1B, RNGTT ALDH1A1 3318/4885CCR5 323/4885HTR2C 4505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.